| 摘要 |
The use of a retinal pericyte apoptosis inhibitor (I) is claimed in the production of a medicament for treating or preventing diabetic retinopathy. An independent claim is included for pharmaceutical compositions containing (I). ACTIVITY : Antidiabetic; Ophthalmological. MECHANISM OF ACTION : Retinal pericyte apoptosis inhibitor; Antioxidant; Phosphatidylcholine phospholipase C inhibitor; Acid sphingomyelinase inhibitor; Caspase inhibitor. In tests in cultured bovine pericytes, tricyclo (5,21,0(2,6)) decyl-9(8)-xanthate (D609) (Ia) at a concentration of 9.4 MicroM inhibited advanced glycosylation end product (AGE)-methylglyoxal induced ceramide production by 95%, diacyl glycerol (DAG) production by 80% and apoptosis by 40%. |
